-
Inflectra
Inflectra (infliximab-dyyb) is a biologic infusion therapy used to treat autoimmune and inflammatory conditions, including certain types of arthritis and bowel disease. As a biosimilar to Remicade®, Inflectra® offers the same clinical benefits while helping improve patient access to advanced therapies.
At Singlepoint Healthcare, Inflectra is administered in a safe, comfortable, and closely monitored environment, with personalized care to support symptom management and disease control.
How Inflectra Works
Inflectra is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), a protein that plays a central role in inflammation. By blocking TNF-α, Inflectra helps reduce inflammation, slow disease progression, and relieve symptoms such as joint pain, swelling, and digestive tract inflammation.
Patients receiving Inflectra often experience improved mobility, reduced flare-ups, and better overall quality of life while managing chronic autoimmune conditions.
Key Details
Important Information
| Category | Details |
|---|---|
| Conditions It Treats | Crohn’s Disease, Ulcerative Colitis, Rheumatoid arthritis |
| Manufacturer | Pfizer Inc. |
| Administered by | Infusion |
| Frequency | 6–8 weeks |
| Length of Infusion | ~2 hours |
| FDA Approval(s) | Crohn’s Disease: Approved April 5, 2016 Rheumatoid Arthritis: Approved April 5, 2016 Ulcerative Colitis: Approved April 5, 2016 |